Very-low-dose twice-daily aspirin maintains platelet inhibition and improves haemostasis during dual-antiplatelet therapy for acute coronary syndrome

Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy

(2018) Wael Sumaya et al.   EUROPEAN HEART JOURNAL

Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients With Multivessel Coronary Disease

(2018) Sameer Bansilal et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention

(2018) Davide Capodanno et al.   Nature Reviews Cardiology

Once- versus twice-daily aspirin treatment in patients with essential thrombocytosis

(2018) Mads Lamm Larsen et al.   PLATELETS

The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting

(2018) Valerio De Stefano et al.   Blood Cancer Journal

Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial

(2018) Pascal Vranckx et al.   LANCET

Type 2 Diabetes, Obesity, and Aspirin Responsiveness ∗

(2017) Carlo Patrono et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

What role will the NHS play in the 2017 election?

(2017) Ben Page   BMJ-British Medical Journal

The impact of medication adherence on clinical outcomes of coronary artery disease: A meta-analysis

(2017) Liping Du et al.   European Journal of Preventive Cardiology

What role will the NHS play in the 2017 election?

(2017) Ben Page   BMJ-British Medical Journal

Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS–TIMI 54

(2016) Deepak L. Bhatt et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease

(2016) Marc P. Bonaca et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial

(2016) Robert F. Storey et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Effects of dabigatran on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel

(2016) Francesco Franchi et al.   THROMBOSIS AND HAEMOSTASIS

Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events

(2016) Marc P. Bonaca et al.   JAMA Cardiology

Drug-Free Platelets Can Act as Seeds for Aggregate Formation During Antiplatelet TherapySignificance

(2015) Thomas Hoefer et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Ticagrelor Protects the Heart Against Reperfusion Injury and Improves Remodeling After Myocardial InfarctionSignificance

(2015) Yumei Ye et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Inhibition of the platelet P2Y 12 receptor for adenosine diphosphate does not impair the capacity of platelet to synthesize thromboxane A 2

(2015) Mariangela Scavone et al.   EUROPEAN HEART JOURNAL

2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

(2015) Marco Roffi et al.   EUROPEAN HEART JOURNAL

Multiple daily doses of acetyl-salicylic acid (ASA) overcome reduced platelet response to once-daily ASA after coronary artery bypass graft surgery: a pilot randomized controlled trial

(2015) J. S. Paikin et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction

(2015) Marc P. Bonaca et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial

(2015) Gregory Ducrocq et al.   EuroIntervention

Chronic Treatment With Ticagrelor Limits Myocardial Infarct Size

(2014) Manjyot K. Nanhwan et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Hypofibrinolysis in type 2 diabetes: the role of the inflammatory pathway and complement C3

(2014) Katharina Hess et al.   DIABETOLOGIA

2014 ESC/EACTS Guidelines on myocardial revascularization

(2014)   EUROPEAN HEART JOURNAL

A Polypill Strategy to Improve Adherence

(2014) José M. Castellano et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes

(2014) Ezra A. Amsterdam et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

COX-2 Protects against Atherosclerosis Independently of Local Vascular Prostacyclin: Identification of COX-2 Associated Pathways Implicate Rgl1 and Lymphocyte Networks

(2014) Nicholas S. Kirkby et al.   PLoS One

In vivo prostacyclin biosynthesis and effects of different aspirin regimens in patients with essential thrombocythaemia

(2014) Isabella Squellerio et al.   THROMBOSIS AND HAEMOSTASIS

Evolving pattern of platelet P2Y12inhibition in patients with acute coronary syndromes

(2013) Rajiv R. Joshi et al.   PLATELETS

Fibrin Clot Structure and Platelet Aggregation in Patients with Aspirin Treatment Failure

(2013) Søs Neergaard-Petersen et al.   PLoS One

Blockade of the purinergic P2Y12 receptor greatly increases the platelet inhibitory actions of nitric oxide

(2013) N. S. Kirkby et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease

(2012) Jean-Guillaume Dillinger et al.   AMERICAN HEART JOURNAL

Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target

(2012) S. Pascale et al.   BLOOD

ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation

(2012) et al.   EUROPEAN HEART JOURNAL

2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction

(2012) Patrick T. O'Gara et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes

(2012) B. ROCCA et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Evaluation of the pharmacokinetics and pharmacodynamics of ticagrelor co-administered with aspirin in healthy volunteers

(2012) Renli Teng et al.   PLATELETS

Ticagrelor Compared With Clopidogrel by Geographic Region in the Platelet Inhibition and Patient Outcomes (PLATO) Trial

(2011) Kenneth W. Mahaffey et al.   CIRCULATION

Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications

(2011) Galia Spectre et al.   THROMBOSIS AND HAEMOSTASIS

Antiplatelet effect of once- or twice-daily aspirin dosage in stable coronary artery disease patients with diabetes

(2010) Faouzi Addad et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation

(2010) P. C. J. ARMSTRONG et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease

(2010) Adeline Vermillet et al.   THROMBOSIS AND HAEMOSTASIS

Impaired anti-platelet effect of aspirin, inflammation and platelet turnover in cardiac surgery☆☆☆

(2010) Hernán Cohen Arazi et al.   Interactive Cardiovascular and Thoracic Surgery

Effects of Aspirin on Clot Structure and Fibrinolysis Using a Novel In Vitro Cellular System

(2009) R.A. Ajjan et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes

(2009) Lars Wallentin et al.   NEW ENGLAND JOURNAL OF MEDICINE